Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

This is a monocentric, randomized, controlled, open label phase IV superiority trial. After signing the informed consent form and upon the confirmation of the patient eligibility, patients will be randomized 1:1 to the experimental arm (NAC + Cisplatin) or the standard arm (Cisplatin). The primary objective of this trial is to evaluate the protecting effect of Lysomucil® 10% against Cisplatin-induced ototoxicity. In this case, we will evaluate its effect through the transtympanic administration in both ears.

Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

Recruitment

Summary

Participation Requirements

Description

Tracking Information